These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 9557291)

  • 1. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between diversity of hepatitis C virus quasispecies and viremia, activity of liver disease and response to interferon therapy].
    Tang X; Qian K; Yuan X; Johnson YN
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):128-31. PubMed ID: 12196822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.
    Neau D; Jouvencel AC; Legrand E; Trimoulet P; Galperine T; Chitty I; Ventura M; Le Bail B; Morlat P; Lacut JY; Ragnaud JM; Dupon M; Fleury H; Lafon ME
    J Med Virol; 2003 Sep; 71(1):41-8. PubMed ID: 12858407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.
    González-Peralta RP; Qian K; She JY; Davis GL; Ohno T; Mizokami M; Lau JY
    J Med Virol; 1996 Jul; 49(3):242-7. PubMed ID: 8818972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus.
    Kato T; Mizokami M; Nakano T; Orito E; Ohba K; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Fujita K; Yasuda K; Iino S
    J Med Virol; 1998 Jun; 55(2):109-17. PubMed ID: 9598930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic variation characteristics of the envelope region of hepatitis C virus in the patients with chronic hepatitis].
    Chen S; Wang Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):219-22. PubMed ID: 12665923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation.
    Hughes MG; Rudy CK; Chong TW; Smith RL; Evans HL; Iezzoni JC; Sawyer RG; Pruett TL
    Liver Transpl; 2004 Feb; 10(2):208-16. PubMed ID: 14762858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary study of hepatitis C virus envelope genes during primary infection.
    Chen S; Wang YM
    Chin Med J (Engl); 2007 Dec; 120(24):2174-80. PubMed ID: 18167197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy.
    Zeuzem S
    Forum (Genova); 2000; 10(1):32-42. PubMed ID: 10717256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.
    Brambilla S; Bellati G; Asti M; Lisa A; Candusso ME; D'Amico M; Grassi G; Giacca M; Franchini A; Bruno S; Ideo G; Mondelli MU; Silini EM
    Hepatology; 1998 Jun; 27(6):1678-86. PubMed ID: 9620342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus.
    Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S
    J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease.
    Brunetto MR; Suzuki T; Aizaky H; Flichman D; Colombatto P; Abate ML; Oliveri F; Matsuura Y; Bonino F; Miyamura T
    Ital J Gastroenterol; 1996 Dec; 28(9):499-504. PubMed ID: 9131394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and therapeutic implications of hepatitis C virus compartmentalization.
    Di Liberto G; Roque-Afonso AM; Kara R; Ducoulombier D; Fallot G; Samuel D; Feray C
    Gastroenterology; 2006 Jul; 131(1):76-84. PubMed ID: 16831592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.